Top Markets
Coin of the day
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc.

OBLN
Rank in Stocks #34657
Obalon Therapeutics, Inc. operates as a fully integrated medical device... Obalon Therapeutics, Inc. operates as a fully integrated medical device enterprise, concentrating its efforts on creating and commercializing innovative solutions for individuals battling obesity. The company's flagship offering is the Obalon Balloon System, specifically engineered to promote weight reduction in obese patients. This comprehensive system incorporates an ingestible capsule that houses an inflatable balloon connected to a microcatheter. It also includes the Obalon Navigation System console, a specialized hardware and software platform used to precisely monitor and display the balloon's location during its placement. Further components are the Obalon Touch Inflation Dispenser, a semi-automated, portable instrument for inflating the balloon once it's correctly positioned, and a single-use canister containing a gas mixture. By February 27, 2020, Obalon Therapeutics managed three company-owned treatment centers situated in California. The firm was established in 2008 and bases its operations in Carlsbad, California.
Share Price
$3.05
Last synced: 2021-06-15
Market Cap
$5.16M
Change (1 day)
-5.86%
Change (1 year)
0.00%
Country
US
Trade Obalon Therapeutics, Inc. (OBLN)

Category

Earnings for Obalon Therapeutics, Inc. (OBLN)
Earnings in 2026 TTM: 0
According to Obalon Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Obalon Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US